home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Parkinson's Disease Therapeutics Conference

 
  June 21, 2010  
     
 
The New York Academy of Sciences, 7 World Trade Center 250 Greenwich Street, 40th floor New York, NY 10007-2157
2010-10-06


www.nyas.org/MJFF4
 
 
Organized by: The New York Academy of Sciences
Invited Speakers:

Speakers

Raymond T. Bartus, PhD

Ceregene, Inc.

Dr. Bartus has over 30 years of experience in the pharmaceutical and biotech industries, involving tenures both at major multi-national companies and smaller, development-stage companies. Dr. Bartus joined Ceregene in December, 2002 and directs all preclinical, clinical and regulatory activities as well as chairs the company's SAB meetings. Prior to joining Ceregene, Dr. Bartus spend 10 years at Alkermes, where he served as Senior Vice President for Preclinical Research and Development. During his tenure at Alkermes, he was directly responsible for the conceptualization, preclinical development and initial clinical strategy for Alkermes' lead proprietary product, Vivitrol (formally called Vivitrex), which has since gained FDA approval. Dr. Bartus was selected to launch and served as Chief Editor for the scholarly journal Neurobiology of Aging. During his 10 years as Chief Editor, it grew to rank as the leading specialized journal in its field. He has also been selected to serve on numerous panels and "think tanks", including for the U.S. Congress' Office of Technology Assessment, Secretary of Health and Human Services, and FDA, among others. He is recognized as one of the founders of the 'Cholinergic Hypothesis', a hypothesis that led directly to the first four drugs approved by the FDA for Alzheimer's disease. He has been honored by ISI (the Institute for Scientific Information) as a "highly cited" researcher, comprising less than 0.5% of all publishing scientists. In addition to helping discover and develop several novel therapies for human diseases, Dr. Bartus has published nearly 250 scholarly papers, chapters, books and special journal issues.

Erwan Bezard, PhD

Université de Bordeaux

Dr. Bezard has authored or co-authored over 120 professional publications in the field of neurobiology, most of which are on Parkinson's disease and related disorders. He is best known for his work on the compensatory mechanisms that mask the progression of Parkinson's disease and on the pathophysiology of levodopa-induced dyskinesia. His current research interests include the study of the compensatory mechanisms, the levodopa-induced dyskinesia, the basic pathophysiology of basal ganglia circuitry, and the development of new strategies to alleviate symptoms and/or to slow disease progression. Dr. Bezard is the director of a new CNRS research unit located in Bordeaux, the Neurodegenerative Disorders Institute, that features preclinical and clinical researchers working towards development of therapeutic solutions. He is also a Visiting Professor at the China Academy of Medical Sciences (Beijing, China) where he has set-up and manages a non-human primate facility dedicated to Movement Disorders. He serves on the board of international organizations such as the International Basal Ganglia Society and The Michael J. Fox Foundation. He is associate editor of Neurobiology of Disease and Movement Disorders, two leading journals in the field. He serves on the editorial boards of several neurobiology journals. Besides consulting for several drug companies in the field of movement disorders, he is a non-executive director of Plenitudes Sarl (France), Motac Neuroscience (UK) and Motac Cognition (USA).

Ann Martin Graybiel, PhD

Massachusetts Institute of Technology

Ann M. Graybiel, Walter A. Rosenblith Professor of Neuroscience and Investigator, McGovern Institute for Brain Research at MIT, was trained at Harvard and MIT and received her PhD from MIT. Research in the Graybiel Laboratory is focused on regions of the forebrain that influence movement, mood and motivation: the basal ganglia and neural pathways interconnecting the basal ganglia with the cerebral cortex. Dr. Graybiel and her group use methods ranging from multi-electrode recordings in awake behaving animals to genetic engineering to analyze these neural pathways. Central to many of these studies is work on brain mechanisms underlying habit formation and repetitive behaviors and understanding how such mechanisms can become dysfunctional in neurologic and neuropsychiatric disorders such as Parkinson’s disease, Huntington’s disease, obsessive-compulsive disorder, and in addictive states. Graybiel was elected to the National Academy of Sciences in 1988, the American Academy of Arts and Sciences in 1991, and the Institute of Medicine in 1994. She was awarded the National Medal of Science in 2001.

Gerard Griffioen, PhD

reMYND NV

Dr. Griffioen holds a PhD degree from the Free University of Amsterdam, where his studies focused on nutritional signalling pathways in yeast. He then held a position as post-doctoral fellow at the University of Vienna (Austria), where he investigated molecular mechanisms regulating subcellular localization of cAMP-dependent protein kinase. From Vienna, Dr. Griffioen went to the University of Leuven (Belgium) where he held a 2-year research position during which he studied the physiological significance of subcellular localisation of signalling pathways. Since 2002 he has held the position of Chief Scientific Officer at reMYND, a biotech spin-off of the University of Leuven. At reMYND he has set-up an innovative technology platform for pre-clinical development (from assay development to proof-of-concept in animal models) of novel, disease-modifying therapeutics in the fields of Alzheimer’s and Parkinson’s diseases. Currently, a rich pipeline of promising programs in both disease areas is actively pursued. A first drug candidate is expected to enter the clinic in early 2010. Dr. Griffioen has been awarded several personal research grants, has published original research papers and reviews in peer-reviewed journals and is inventor on several patents. In 2004, reMYND was awarded most innovative start up company in Flanders.

J. William Langston, MD

The Parkinson’s Institute

J. William Langston is a graduate of the University of Missouri School of Medicine and was formerly a faculty member at Stanford University and chairman of neurology at Santa Clara Valley Medical Center in San Jose, California. Langston has authored or co-authored over 250 professional publications in the field of neurology, most of which are on Parkinson's disease and related disorders. He is perhaps best known for the discovery of the biologic effects of MPTP, an experimental neurotoxin that is widely used in the study of Parkinson's disease. Langston's current research interests include the study of mechanisms of neuronal degeneration, the etiology of Parkinson's disease, and the development of new strategies to slow or halt disease progression. He has received numerous awards, including the Distinguished Achievement Award from Modern Medicine, the Sarah M. Poiley Award from the New York Academy of Sciences, the 30th Anniversary Award from the Parkinson's Disease Foundation, the Distinguished Clinical Investigator Award from Roche Pharmaceuticals, and most recently the 1999 Movement Disorders Research Award from the American Academy of Neurology.

Patrick Little, PhD

Adolor Corporation

Dr. Little received his BS in psychology from the College of William and Mary in 1981 and his PhD in pharmacology and toxicology from the Medical College of Virginia in 1989. His doctoral research focused on the behavioral and neurochemical effects of cannabinoids with the goal of trying to identify cannabinoid analogs that had distinct behavioral and neurochemical profiles. He was a postdoctoral fellow from 1989 – 1990 in the Psychiatry Department at Washington University Medical School and from 1990 – 1997 in the Pharmacology Department at Duke University Medical School. The focus of his postdoctoral research was studying the effects of a number of drugs of abuse on endocrine function. He joined the Pharmacology Department at Adolor Corporation in 1997 as part of the in vivo Pharmacology group and now serves as Principal Research Investigator.

Kenneth Marek, MD

Institute for Neurodegenerative Disorders

Kenneth L. Marek graduated from Princeton University with a degree in biochemistry, and received his MD from Yale University. He was trained in internal medicine and neurology at the Johns Hopkins School of Medicine and is board certified in both of these specialties. He received further training as a post-doctoral fellow in neurochemistry at the Institute of Neurology, Queens Square, London. He was a faculty member at the Johns Hopkins School of Medicine and then at Yale University School of Medicine before starting the Institute for Neurodegenerative Disorders. Marek has been a recipient of the National Parkinson's Foundation Richard E. Heikkala Research Scholar Award. His major research interests include identification of biomarkers for early detection, assessment of disease progression and development of new treatments for Parkinson's disease and related neurodegenerative disorders, including Huntington's disease and dystonia. His specific interest has been in in vivo neuroreceptor imaging in Parkinson's disease and related disorders. He has authored numerous neurology and neuroscience publications on these topics. Marek is the principal investigator of several multi-center international studies investigating the use of imaging to assess the onset, progression, and effect of treatment in Parkinson's disease.

Jeremy R. Nichols, PhD

The Parkinson’s Institute

R. Jeremy Nichols obtained a BS degree with honors from Austin Peay State University where he was involved in field biology studies. He then obtained a PhD. in the laboratory of Paula Traktman at the Medical College of Wisconsin. While there, he studied a novel family of protein kinases and found that they are required for meiotic cell division. He also studied proteins involved in the infectious cycle of the small pox vaccine agent-vaccinia virus. He pursued his interest in cellular signaling to the United Kingdom Medical Research Council Protein Phosphorylation Unit to unravel the role of LRRK2 in cells and how disease associated mutations cause Parkinson’s disease.

Gregory A. Petsko, PhD

Brandeis University

Greg Petsko is one of the world’s leading biochemists. For over 30 years he has used protein crystallography, molecular biology and genetics to probe the relationship between protein structure and function. Starting his college career as a major in classical literature, Prof. Petsko eventually completed a D. Phil. in Molecular Biophysics as a Rhodes Scholar at the University of Oxford, England, and a postdoc in biochemistry at the Sorbonne in Paris. Following a stint as a junior faculty member of the Department of Biochemistry at Wayne State University School of Medicine, he moved to MIT, becoming Professor of Chemistry in 1985. In 1990 he moved to Brandeis, where in 1995 he was named the third Director of the Rosenstiel Basic Medical Sciences Research Center, a position he held until 2008, when he stepped down to become Chair of the Department of Biochemistry. He is also Adjunct Professor of Neurology at Harvard Medical School and the Brigham & Women’s Hospital. In 2007 he was elected President of the American Society for Biochemistry and Molecular Biology, and in 2009 he became President-elect of the International Union of Biochemistry and Molecular Biology, the largest federation of scientific societies in the world. He has been elected to the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences, and is one of only a handful of foreigners ever elected honorary member of the Biochemical Society of Japan. For ten years he has written a widely quoted monthly column on science and society for the journal Genome Biology. His scientific interests remain grounded in questions of macromolecular structure and function, but for the last six years he and his scientific partner, Professor Dagmar Ringe, have largely focused their research on the prevention and treatment of neurodegenerative diseases.

David E. Vaillancourt, PhD

University of Illinois at Chicago

Dr. Vaillancourt earned his masters and PhD from Pennsylvania State University. He then completed a post-doctoral fellowship at the University of Illinois at Chicago (UIC) in neurophysiology and neuroimaging. He has been supported by NIH at each level of his academic career. He directs a laboratory that studies health and pathological motor control using structural and functional brain imaging. He is currently an associate professor in kinesiology and nutrition at UIC. He holds secondary appointments in bioengineering, neurology, and the interdisciplinary training program in neuroscience at UIC.

 
Deadline for Abstracts: 2010-10-06
 
Registration: www.nyas.org/MJFF4
E-mail: cau@nyas.org
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.